Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in Ann Oncol

Retrieve available abstracts of 98 articles:
HTML format
Text format



Single Articles


    April 2018
  1. GEFFEN DB
    Should decisions on adding adjuvant chemotherapy in early stage ER positive breast cancer be based on gene expression testing or clinicopathologic factors or both?
    Ann Oncol. 2018 Apr 4. pii: 4959909. doi: 10.1093.
    PubMed     Text format    


  2. CRUZ C, Castroviejo-Bermejo M, Gutierrez-Enriquez S, Llop-Guevara A, et al
    RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA mutated breast cancer.
    Ann Oncol. 2018 Apr 4. pii: 4959904. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2018
  3. CORTES J, Perez-Garcia J, Levy C, Gomez Pardo P, et al
    Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer.
    Ann Oncol. 2018 Feb 21. pii: 4897992. doi: 10.1093.
    PubMed     Text format     Abstract available


  4. MARTIN M, Campone M, Bondarenko I, Sakaeva D, et al
    Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane.
    Ann Oncol. 2018 Feb 10. pii: 4852792. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2018
  5. TAN WW, Hillman DW, Salim M, Northfelt DW, et al
    N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial.
    Ann Oncol. 2018 Jan 29. pii: 4829660. doi: 10.1093.
    PubMed     Text format    


  6. BARECHE Y, Venet D, Ignatiadis M, Aftimos P, et al
    Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.
    Ann Oncol. 2018 Jan 22. pii: 4819112. doi: 10.1093.
    PubMed     Text format     Abstract available


  7. HARTMAIER RJ, Trabucco SE, Priedigkeit N, Chung JH, et al
    Recurrent hyperactive ESR1 fusion proteins in endocrine therapy resistant breast cancer.
    Ann Oncol. 2018 Jan 19. pii: 4817340. doi: 10.1093.
    PubMed     Text format     Abstract available


  8. ABBOSH C, Swanton C, Birkbak NJ
    Circulating tumor DNA analyses reveal novel resistance mechanisms to CDK inhibition in metastatic breast cancer.
    Ann Oncol. 2018 Jan 17. pii: 4815740. doi: 10.1093.
    PubMed     Text format    


  9. TURNER NC, Finn RS, Martin M, Im SA, et al
    Clinical Considerations of the Role of Palbociclib in the Management of Advanced Breast Cancer Patients With and Without Visceral Metastases.
    Ann Oncol. 2018 Jan 11. pii: 4802189. doi: 10.1093.
    PubMed     Text format     Abstract available


  10. SOMASHEKHAR SP, Sepulveda MJ, Puglielli S, Norden AD, et al
    Watson for Oncology and breast cancer treatment recommendations: agreement with an expert multidisciplinary tumor board.
    Ann Oncol. 2018 Jan 9. pii: 4781689. doi: 10.1093.
    PubMed     Text format     Abstract available


  11. SWAIN SM, Schneeweiss A, Gianni L, Gao JJ, et al
    Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.
    Ann Oncol. 2018 Jan 2. pii: 4782676. doi: 10.1093.
    PubMed     Text format    


    December 2017
  12. KHOSROW-KHAVAR F, Yin H, Barkun A, Bouganim N, et al
    Aromatase Inhibitors and the Risk of Colorectal Cancer in Post-Menopausal Women with Breast Cancer.
    Ann Oncol. 2017 Dec 27. pii: 4779926. doi: 10.1093.
    PubMed     Text format     Abstract available


  13. SHARMA P, Barlow WE, Godwin AK, Pathak H, et al
    Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with doxorubicin-based adjuvant chemotherapy (SWOG S9313).
    Ann Oncol. 2017 Dec 23. pii: 4774220. doi: 10.1093.
    PubMed     Text format     Abstract available


  14. SWAIN SM, Ewer MS, Viale G, Delaloge S, et al
    Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study
    Ann Oncol. 2017 Dec 15. pii: 4748818. doi: 10.1093.
    PubMed     Text format     Abstract available


  15. CONDORELLI R, Spring L, O'Shaughnessy J, Lacroix L, et al
    Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.
    Ann Oncol. 2017 Dec 11. pii: 4725051. doi: 10.1093.
    PubMed     Text format     Abstract available


  16. GENNARI A, Sun Z, Hasler-Strub U, Colleoni M, et al
    A randomized phase II study evaluating different maintenance schedules of nab-Paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial.
    Ann Oncol. 2017 Dec 8. pii: 4710349. doi: 10.1093.
    PubMed     Text format     Abstract available


  17. PALUCH-SHIMON S, Peccatori FA
    BRCA 1 and 2 mutation status: the elephant in the room during oncofertility counseling for young breast cancer patients.
    Ann Oncol. 2017 Dec 5. pii: 4693825. doi: 10.1093.
    PubMed     Text format    


    November 2017
  18. FRANCIS PA
    Male Breast Cancer: Pink Ribbon Blues.
    Ann Oncol. 2017 Nov 20. doi: 10.1093.
    PubMed     Text format    


  19. BUISSERET L, Pommey S, Allard B, Garaud S, et al
    Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.
    Ann Oncol. 2017 Nov 14. doi: 10.1093.
    PubMed     Text format     Abstract available


  20. SESTAK I, Smith SG, Howell A, Forbes JF, et al
    Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.
    Ann Oncol. 2017 Nov 6. doi: 10.1093.
    PubMed     Text format     Abstract available


  21. PATEL R, Maxwell S, Yan D, Dressler EV, et al
    Medical Oncologists' Perception of Anti-Estrogen Therapy Benefit in Premenopausal Women with Hormone Receptor-Positive Early Breast Cancer.
    Ann Oncol. 2017 Nov 2. doi: 10.1093.
    PubMed     Text format    


    October 2017
  22. KOK M
    LAG-3: another brake to release in breast cancer?
    Ann Oncol. 2017 Oct 30. doi: 10.1093.
    PubMed     Text format    


  23. CARDOSO F, Bartlett JMS, Slaets L, van Deurzen CHM, et al
    Characterization of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
    Ann Oncol. 2017 Oct 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  24. BLACKWELL K, Gascon P, Krendyukov A, Gattu S, et al
    Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase 3, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppr
    Ann Oncol. 2017 Oct 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  25. CRISCITIELLO C, Bayar MA, Curigliano G, Symmans FW, et al
    A gene signature to predict high tumour-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple negative breast cancer.
    Ann Oncol. 2017 Oct 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  26. MOBUS V, Jackisch C, Lueck HJ, du Bois A, et al
    Ten-year Results of Intense Dose-dense chemotherapy show superior survival compared to a conventional schedule in High-risk Primary Breast Cancer: Final results of AGO Phase III iddEPC trial.
    Ann Oncol. 2017 Oct 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  27. NUCIFORO P, Pascual T, Cortes J, Llombart-Cussac A, et al
    A predictive model of pathological response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade.
    Ann Oncol. 2017 Oct 12. doi: 10.1093.
    PubMed     Text format     Abstract available


  28. NABIEVA N, Kellner S, Fehm T, Haberle L, et al
    Patient and tumor characteristics and their influence on early therapy persistence with letrozole in postmenopausal patients with early breast cancer.
    Ann Oncol. 2017 Oct 10. doi: 10.1093.
    PubMed     Text format     Abstract available


  29. LAMBERTINI M, Goldrat O, Ferreira AR, Dechene J, et al
    Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients.
    Ann Oncol. 2017 Oct 10. doi: 10.1093.
    PubMed     Text format     Abstract available


  30. FRIBBENS C, Garcia Murillas I, Beaney M, Hrebien S, et al
    Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer.
    Ann Oncol. 2017 Oct 4. doi: 10.1093.
    PubMed     Text format     Abstract available


  31. FUJII T, Kogawa T, Dong W, Sahin AA, et al
    Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer.
    Ann Oncol. 2017;28:2420-2428.
    PubMed     Text format     Abstract available


    September 2017
  32. HAN HS, Dieras V, Robson M, Palacova M, et al
    Veliparib With Temozolomide or Carboplatin/Paclitaxel Versus Placebo With Carboplatin/Paclitaxel in Patients With BRCA1/2 Locally Recurrent/Metastatic Breast Cancer: Randomized Phase II Study.
    Ann Oncol. 2017 Sep 29. doi: 10.1093.
    PubMed     Text format     Abstract available


  33. BURUGU S, Gao D, Leung S, Chia SK, et al
    LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors.
    Ann Oncol. 2017 Sep 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  34. CURIGLIANO G, Burstein HJ, Winer EP, Gnant M, et al
    Reply to "The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by Kirova et al.
    Ann Oncol. 2017 Sep 25. doi: 10.1093.
    PubMed     Text format    


  35. KIROVA YM, Carroll S, Fourquet A, Offersen B, et al
    The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology.
    Ann Oncol. 2017 Sep 22. doi: 10.1093.
    PubMed     Text format    


  36. CHAJES V, Assi N, Biessy C, Ferrari P, et al
    A prospective evaluation of plasma phospholipid fatty acids and breast cancer risk in the EPIC study.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed     Text format     Abstract available


  37. MESSINA C, Messina M, Zanardi E
    Risks and benefits from CDK inhibitors for advanced HR+ Her 2- breast cancer.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed     Text format    


  38. BUTTERBAUGH ST, Patel R, Romond EH, Mathew A, et al
    Trastuzumab use in patients with durable complete response in HER2-amplified metastatic breast cancer: To continue or not to continue.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed     Text format    


  39. NITZ UA, Gluz O, Christgen M, Grischke EM, et al
    De-escalation strategies in HER2-positive early breast cancer (EBC): Final analysis of the WSG-ADAPT HER2+/HR- phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekl
    Ann Oncol. 2017 Sep 4. doi: 10.1093.
    PubMed     Text format     Abstract available


  40. REGAN MM, Walley BA, Francis PA, Fleming GF, et al
    Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT.
    Ann Oncol. 2017;28:2225-2232.
    PubMed     Text format     Abstract available


  41. HAMY AS, Pierga JY, Sabaila A, Laas E, et al
    Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer.
    Ann Oncol. 2017;28:2233-2240.
    PubMed     Text format     Abstract available


  42. BERNICHON E, Vallard A, Wang Q, Attignon V, et al
    Genomic alterations and radioresistance in breast cancer: an analysis of the ProfiLER protocol.
    Ann Oncol. 2017 Sep 1. doi: 10.1093.
    PubMed     Text format     Abstract available


  43. VAN BOCKSTAL M, Libbrecht L, Floris G, Lambein K, et al
    Stromal inflammation, necrosis and HER2 overexpression in ductal carcinoma in situ of the breast: another causality dilemma?
    Ann Oncol. 2017;28:2317.
    PubMed     Text format    


    August 2017
  44. CHUNG JH, Pavlick D, Hartmaier R, Schrock AB, et al
    Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.
    Ann Oncol. 2017 Aug 31. doi: 10.1093.
    PubMed     Text format     Abstract available


  45. CURIGLIANO G, Burstein HJ, P Winer E, Gnant M, et al
    De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
    Ann Oncol. 2017;28:1700-1712.
    PubMed     Text format     Abstract available


  46. DEL MASTRO L, Lambertini M
    Gonadotropin-releasing hormone analogs for ovarian function protection during chemotherapy in young early breast cancer patients: the last piece of the puzzle?
    Ann Oncol. 2017;28:1683-1685.
    PubMed     Text format    


  47. GERMA C, Miller M, Mukhopadhyay P, Hewes B, et al
    Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib.
    Ann Oncol. 2017;28:2021-2024.
    PubMed     Text format    


    July 2017

  48. Appendix 2: Advanced breast cancer: MCBS eUpdate published online 25 April 2017 (www.esmo.org/Guidelines/Breast-Cancer).
    Ann Oncol. 2017;28.
    PubMed     Text format    


    June 2017
  49. OHGAMI M, Bando H, Ishiguro H, Tsuda M, et al
    Effect of dose timing on the blood concentration of lapatinib in patients with breast cancer.
    Ann Oncol. 2017 Jun 26. doi: 10.1093.
    PubMed     Text format    


  50. BLACKWELL K, Gascon P, Jones CM, Nixon A, et al
    Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.
    Ann Oncol. 2017 Jun 16. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2017
  51. ALI HR, Dariush A, Thomas J, Provenzano E, et al
    Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial.
    Ann Oncol. 2017 May 19. doi: 10.1093.
    PubMed     Text format     Abstract available


  52. SPERA G, Fresco R, Fung H, Dyck JRB, et al
    Beta Blockers and Improved Progression Free Survival in Patients with Advanced HER2 Negative Breast Cancer: a Retrospective Analysis of the ROSE/TRIO-012 Study.
    Ann Oncol. 2017 May 18. doi: 10.1093.
    PubMed     Text format     Abstract available


  53. SASADA S, Kurihara H, Kinoshita T, Yoshida M, et al
    64Cu-DOTA-Trastuzumab PET imaging for HER2-specific primary lesions of breast cancer.
    Ann Oncol. 2017 May 15. doi: 10.1093.
    PubMed     Text format    


  54. MAMIYA H, Tahara RK, Tolaney SM, Choudhry N, et al
    Cost-Effectiveness of Palbociclib in Hormone Receptor-Positive Advanced Breast Cancer.
    Ann Oncol. 2017 May 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  55. LEONARD R, Adamson D, Bertelli G, Mansi J, et al
    GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial.
    Ann Oncol. 2017 May 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  56. LESURF R, Griffith OL, Griffith M, Hundal J, et al
    Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial.
    Ann Oncol. 2017;28:1070-1077.
    PubMed     Text format     Abstract available


    April 2017
  57. KUIJER A, Verloop J, Visser O, Sonke G, et al
    The influence of socio-economic status and ethnicity on adjuvant systemic treatment guideline adherence for early stage breast cancer in the Netherlands.
    Ann Oncol. 2017 Apr 29. doi: 10.1093.
    PubMed     Text format     Abstract available


  58. MOEBUS V, von Minckwitz G, Jackisch C, Luck HJ, et al
    German Adjuvant Intergroup Node-positive Study (GAIN): A Phase III Trial Comparing Two Dose-Dense Regimens (iddEPC vs. ddEC-PwX) in High-Risk Early Breast Cancer Patients.
    Ann Oncol. 2017 Apr 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  59. EARL HM, Hiller L, Dunn J, Blenkinsop C, et al
    Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial.
    Ann Oncol. 2017 Apr 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  60. WEIN L, Savas P, Van Geelan C, Caramia F, et al
    FGFR2 amplification in metastatic hormone positive breast cancer and response to an mTOR inhibitor.
    Ann Oncol. 2017 Apr 18. doi: 10.1093.
    PubMed     Text format    


    March 2017
  61. YERUSHALMI R, Dong B, Chapman JW, Goss PE, et al
    Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials.
    Ann Oncol. 2017 Mar 31. doi: 10.1093.
    PubMed     Text format     Abstract available


  62. TREDAN O, Menetrier-Caux C, Ray-Coquard I, Garin G, et al
    ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients.
    Ann Oncol. 2017 Mar 24. doi: 10.1093.
    PubMed     Text format    


  63. CURIGLIANO G, Goldhirsch A
    Dual HER2 inhibition and pathological complete response in early breast cancer: increasing success of treatment by improving patient selection.
    Ann Oncol. 2017;28:441-443.
    PubMed     Text format    


    February 2017
  64. LESURF R, Griffith OL, Griffith M, Hundal J, et al
    Genomic characterisation of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy - results from the ACOSOG Z1041 (Alliance) trial.
    Ann Oncol. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  65. CARDOSO F, Costa A, Senkus E, Aapro M, et al
    3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).
    Ann Oncol. 2017 Feb 19. doi: 10.1093.
    PubMed     Text format    


  66. CURIGLIANO G, Goldhirsch A
    Dual HER2 inhibition and pathological complete response in early breast cancer: increasing success of treatment by improving patient selection.
    Ann Oncol. 2017 Feb 7. doi: 10.1093.
    PubMed     Text format    


  67. PRUNERI G, Lazzeroni M, Bagnardi V, Tiburzio GB, et al
    The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast.
    Ann Oncol. 2017;28:321-328.
    PubMed     Text format     Abstract available


  68. YANG TO, Cairns BJ, Reeves GK, Green J, et al
    Cancer risk among 21st century blood transfusion recipients.
    Ann Oncol. 2017;28:393-399.
    PubMed     Text format     Abstract available


  69. MAKKOUK A, Sundaram V, Chester C, Chang S, et al
    Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy.
    Ann Oncol. 2017;28:415-420.
    PubMed     Text format     Abstract available


    January 2017
  70. SWAIN SM, Schneeweiss A, Gianni L, Gao JJ, et al
    Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.
    Ann Oncol. 2017 Jan 5. pii: mdw695. doi: 10.1093.
    PubMed     Text format     Abstract available


  71. PIERGA JY, Bidard FC, Autret A, Petit T, et al
    Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab.
    Ann Oncol. 2017;28:103-109.
    PubMed     Text format    


  72. NASLUND-KOCH C, Nordestgaard BG, Bojesen SE
    Common breast cancer risk alleles and risk assessment: a study on 35 441 individuals from the Danish general population.
    Ann Oncol. 2017;28:175-181.
    PubMed     Text format    


  73. CARDOSO F, Costa A, Senkus E, Aapro M, et al
    3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).
    Ann Oncol. 2017;28:16-33.
    PubMed     Text format    


  74. COSTA R, Carneiro BA, Wainwright DA, Santa-Maria CA, et al
    Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives.
    Ann Oncol. 2017;28:44-56.
    PubMed     Text format    


    December 2016
  75. M-RABET M, Cabaud O, Josselin E, Finetti P, et al
    Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer.
    Ann Oncol. 2016 Dec 20. pii: mdw678. doi: 10.1093.
    PubMed     Text format     Abstract available


  76. KHOSROW-KHAVAR F, Filion KB, Al-Qurashi S, Torabi N, et al
    Cardiotoxicity of Aromatase Inhibitors and Tamoxifen in Post-Menopausal Women with Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Ann Oncol. 2016 Dec 20. pii: mdw673. doi: 10.1093.
    PubMed     Text format     Abstract available


  77. PAGANI O, Klingbiel D, Ruhstaller T, Nole F, et al
    Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99.
    Ann Oncol. 2016 Dec 19. pii: mdw622. doi: 10.1093.
    PubMed     Text format     Abstract available


  78. BELL R, Brown J, Parmar M, Toi M, et al
    Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  79. MATULONIS UA, Wulf GM, Barry WT, Birrer M, et al
    Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high grade serous ovarian and breast cancer.
    Ann Oncol. 2016 Dec 19. pii: mdw672. doi: 10.1093.
    PubMed     Text format     Abstract available


  80. CARDOSO F, Costa A, Senkus E, Aapro M, et al
    3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).
    Ann Oncol. 2016.
    PubMed     Text format    


    November 2016
  81. CARDOSO F, Harbeck N, Barrios CH, Bergh J, et al
    Research needs in breast cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  82. LOIBL S, Jackisch C, Schneeweiss A, Schmatloch S, et al
    Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  83. MARTIN M, Chan A, Dirix L, O'Shaughnessy J, et al
    A randomized adaptive phase II/III study of buparlisib, a pan-Class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    October 2016
  84. NASLUND-KOCH C, Nordestgaard BG, Bojesen SE
    Common breast cancer risk alleles and risk assessment: A study on 35,441 individuals from the Danish general population.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  85. COSTA R, Carneiro BA, Wainwright DA, Santa-Maria CA, et al
    Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    September 2016
  86. NITZ U, Gluz O, Huober J, Kreipe HH, et al
    Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.
    Ann Oncol. 2016.
    PubMed     Text format    


    August 2016
  87. WOODS LM, Morris M, Rachet B
    No 'cure' within 12 years of diagnosis amongst breast cancer patients who are diagnosed via mammographic screening: women diagnosed in the West Midlands region of England 1989-2011.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  88. VUYLSTEKE P, Huizing M, Petrakova K, Roylance R, et al
    Pictilisib plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  89. MAVROUDIS D, Matikas A, Malamos N, Papakotoulas P, et al
    Dose-dense FEC followed by Docetaxel versus Docetaxel plus Cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: A multicenter randomized study by the Hellenic Oncology Research Group
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  90. VRDOLJAK E, Marschner N, Zielinski C, Gligorov J, et al
    Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  91. DIECI MV, Prat A, Tagliafico E, Pare L, et al
    Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    July 2016
  92. DELALOGE S, Perol D, Courtinard C, Brain E, et al
    Paclitaxel plus Bevacizumab or Paclitaxel as First-line Treatment for HER2-Negative Metastatic Breast Cancer in a Multicenter National Observational Study.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    June 2016
  93. JERUSALEM G, Mariani G, Ciruelos EM, Martin M, et al
    Safety of Everolimus Plus Exemestane In Patients With Hormone-Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Progressing on Prior Non-Steroidal Aromatase Inhibitors: Primary Results of a Phase 3b, Open-Label, Single-Arm,
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  94. GOEL S, Krop IE
    PIK3CA mutations in HER2-positive breast cancer - an ongoing conundrum.
    Ann Oncol. 2016.
    PubMed     Text format    


    May 2016
  95. WINTER C, Nilsson MP, Olsson E, George AM, et al
    Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests one third of mutations are somatic.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  96. LOIBL S, Majewski I, Guarneri V, Nekljudova V, et al
    PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer - pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  97. PIVOT X, Marme F, Koenigsberg R, Guo M, et al
    Pooled analyses of eribulin in metastatic breast cancer patients with at least 1 prior chemotherapy.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    November 2015
  98. RODRIGUEZ-WALLBERG K, Turan V, Munster P, Oktay K, et al
    Can ovarian suppression with gonadotropin releasing hormone analogs (GnRHa) preserve fertility in cancer patients?
    Ann Oncol. 2015.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: